MSD India has signed several agreements around molnupiravir during the pandemic, and says that going forward, its focus for the Indian market would be vaccines and oncology. In an interview with Sohini Das, Rehan A Khan, Managing Director, MSD India Region speaks about how the firm expects HPV vaccination to become a part of the national immunisation mission. Edited excerpts:
How has business fared during the past two years of the pandemic?
The year 2021 was a defining one in India's healthcare landscape. As one of the five fastest growing MNCs in India, we had successfully announced non-exclusive voluntary licensing agreements for the drug molnupiravir (an investigational oral antiviral medicine that significantly reduces the risk of hospitalisation or death) with